medoclav
medochemie ltd. - amoksicilinas/klavulano rūgštis - milteliai geriamajai suspensijai - 400 mg/57 mg/5 ml - amoxicillin and beta-lactamase inhibitor
ikelan
medochemie ltd. - atenololis - plėvele dengtos tabletės - 50 mg - atenolol
suphrex
lv system service sia - sunitinibas - kietosios kapsulės - 50 mg - sunitinib
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
medorisper
medochemie ltd. - risperidonas - plėvele dengtos tabletės - 2 mg; 4 mg - risperidone
lorazepam sanoswiss [lorazepam rivopharm]
sanoswiss, uab - lorazepamas - tabletės - 2,5 mg - lorazepam
zinforo
pfizer ireland pharmaceuticals - ceftarolino fosamilis - community-acquired infections; skin diseases, infectious; pneumonia - antibacterials sisteminio naudojimo, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.
xorafia
lv system service sia - sorafenibas - plėvele dengtos tabletės - 200 mg - sorafenib
losartan potassium stada
stada arzneimittel ag - losartano kalio druska - plėvele dengtos tabletės - 100 mg - losartan
qaialdo
nova laboratories ireland limited - spironolaktonas - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 ir 5.